Select Language
Free Registration

GP41

GP41 Overview

English NameTransmembrane glycoprotein gp41Approved Drugs2
Drugs in Clinical Trials11Target SynonymSubmitted name: Transmembrane glycoprotein gp41，env，HIV Envelope Protein gp41，Env polyprotein
Highest Development StageApproved
English NameTransmembrane glycoprotein gp41
Target SynonymSubmitted name: Transmembrane glycoprotein gp41，env，HIV Envelope Protein gp41，Env polyprotein
Approved Drugs2
Drugs in Clinical Trials11
Highest Development StageApproved

Product Inquiry

GP41 Synonyms

HIV-1 (HXB2) GP41,GP41

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
SifuvirtideFS-0101; SFTPhase 2 ClinicalTianjin Fusogen Pharmaceuticals IncAcquired Immunodeficiency Syndrome; HIV Infections
Details
LP-51LP-51Phase 2 ClinicalInstitute Of Pathogenic Biology Chinese Academy Of Medical SciencesHIV Infections; Sjogren's Syndrome
Details
LP-98LP-98Phase 2 ClinicalShanxi Kangbao Biological Product Co LtdHIV Infections
Details
PGT-121PGT-121Phase 2 ClinicalInternational Aids Vaccine Initiative, Theraclone Sciences Inc, The Scripps Research Institute Inc, The Ragon Institute Of Mgh, Mit And HarvardHIV Infections; Acquired Immunodeficiency Syndrome; Retroviridae Infections; Sexually Transmitted Diseases, Viral
Details
MPER-656 liposome vaccineMPER-656Phase 1 ClinicalNational Institute Of Allergy And Infectious Diseases (Niaid)HIV Infections
Details
Microbicide monoclonal antibody triple combination (Polymun Scientific Immunobiologische Forschung)Phase 1 ClinicalPolymun Scientific GmbhHIV Infections
Details
ElipovimabGS-9722Phase 1 ClinicalGilead IncHIV Infections
Details
CPT-31CPT-31; CPT31-LAPhase 1 ClinicalNavigenPurpura, Thrombocytopenic, Idiopathic; HIV Infections
Details
Microbicide Monoclonal Antibody Triple Combination (Polymun)Phase 1 ClinicalHIV Infections
Details
HIV vaccine (influenza virus carrier) (Polymun/Lionex)Phase 1 ClinicalHIV Infections
Details
FB-1002(Frontier Biotechnologies)FB-1002(前沿生物)Phase 1 ClinicalFrontier Biotechnologies Inc, Shanghai Institute Of Materia Medica, Chinese Academy Of SciencesCoronavirus Disease 2019 (COVID-19)
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
AlbuvirtideFB-006MApprovedFrontier Biotechnologies Inc艾可宁Mainland ChinaHIV InfectionsFrontier Biotechnologies Inc2018-05-23Acquired Immunodeficiency Syndrome; HIV Infections
Details
EnfuvirtideT-20; R-698; DP-178ApprovedF. Hoffmann-La Roche LtdFuzeonUnited StatesHIV InfectionsF. Hoffmann-La Roche Ltd2003-03-13HIV Infections; Acquired Immunodeficiency Syndrome
Details
  • Overview
  • Product Inquiry
  • Marketed Drug Information
  • Clinical Drug Information
Share to:

Join UsLegalSite MapPrivacy PolicyTerms and Conditions
Website Feedback
Contact Us

お問い合わせ
グローバル：+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8